Guardant Health Inc (NASDAQ:GH) finished Friday with a subtraction of -$0.42 to close at $29.64, a downside of -1.40 percent. An average of 2,076,680 shares of common stock have been traded in the last five days. There was a gain of $3.71 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,151,775 shares traded, while the 50-day average volume stands at 1,633,334.
GH stock has decreased by -25.84% in the last month. The company shares reached their 1-month lowest point of $25.41 on 09/22/23. With the stock rallying to its 52-week high on 08/30/23, shares of the company touched a low of $20.67 and a high of $62.75 in 52 weeks. It has reached a new high 21 times so far this year and achieved 8.97% or $2.44 in price. In spite of this, the price is down -52.76% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GH stock investors should be aware that Guardant Health Inc (GH) stock had its last reported insider trading activity 18 days ago on Sep 12. In this transaction, the insider spent $69,254. Director, Joyce Meghan V., disposed of 100 shares at a price of $35.01 on Sep 05. The insider now owns more than $3,501 worth of shares. Prior to that, Director Joyce Meghan V. went on to Sale 2,766 shares at $37.55 each on Jun 15. An amount of $103,863 was transacted.
Valuation Metrics
Guardant Health Inc (GH) stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.84, the price-to-book (PB) ratio at 11.91.
Financial Health
The quick ratio of Guardant Health Inc for the three months ended June 29 was 6.65, and the current ratio was 6.96, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 4.57 and a total debt to equity ratio of 4.65 for the quarter ending June 29. Its gross profit as reported stood at $293.21 million compared to revenue of $449.54 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$72.77 million in the quarter, while revenues of -$133.53 million were shrunk -215.28%. The analyst consensus anticipated Guardant Health Inc’s latest quarter earnings to come in at -$1.17 per share, but it turned out to be -$0.67, a 42.70% surprise. For the quarter, EBITDA amounted to -$110.42 million. Shareholders own equity worth $117.69 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Guardant Health Inc (GH) price momentum. RSI 9-day as of the close on 29 September was 49.54%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.81%.
As of today, GH’s price is $27.88 +14.31% or $3.71 from its 5-day moving average. GH is currently trading -24.16% lower than its 20-day SMA and +25.97% higher than its 100-day SMA. However, the stock’s current price level is -20.56% below the SMA50 and -35.52% below the SMA200.
The stochastic %K and %D were 41.59% and 25.95%, respectively, and the average true range (ATR) was 1.68. With the 14-day stochastic at 52.55% and the average true range at 1.68, the RSI (14) stands at 43.88%. The stock has reached 1.73 on the 9-day MACD Oscillator while the 14-day reading was at 0.54.
Analyst Ratings
Bernstein launched coverage on Guardant Health Inc (NASDAQ: GH) in its analyst report released on September 28, 2023. The firm assigned the stock an Outperform rating. The consensus rating for Guardant Health Inc (GH) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell GH, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 17 others rate it as a “buy”.
What is GH’s price target for the next 12 months?
Analysts predict a range of price targets between $34.00 and $85.00, with a median target of $53.00. Taking a look at these predictions, the average price target given by analysts for Guardant Health Inc (GH) stock is $54.29.
